The new date for the Annual General Meeting is June 26 2012 at 13.00
Norwegian time.

Notice of the Annual General Meeting will be issued
in a separate notice.
Contact:

Henrik Lund, CEO

Telephone: 47 90971219

e-mail:
henrik.lund@diagenic.com
About DiaGenic ASA

DiaGenic seeks to create value for patients,
partners, and investors by developing innovative and more patient
friendly methods for early detection of diseases utilizing DiaGenic's
unique concept. The concept implies that a disease evokes systemic
responses in the blood unique for the disease, and which can be measured
by using blood samples.

DiaGenic is a world leader in identifying
these gene expression signatures in peripheral blood and is focused on
the development of biomarkers in the field of Alzheimer's disease and
Parkinson's disease. DiaGenic's Alzheimer's disease development program
includes the CE marked diagnostic test ADtect®, for detection of mild to
moderate Alzheimer's disease, and MCItect®which is under development for
identifying patients with very early stages of Alzheimer's disease
(prodromal AD).

DiaGenic's concept is protected through an extensive
patent portfolio. DiaGenic promotes its products and services towards
leading pharmaceutical, imaging and diagnostic companies. DiaGenic is
located in Norway and listed on the Oslo Stock Exchange. For more
information please visit: www.diagenic.com